Pharmacogenetic testing prices span a wide range — from under $50 for a report generated from existing consumer genetic data, to $2,000 or more for a full clinical panel ordered through a specialty lab. The price depends on whether you need new lab work, whether a clinician has to order the test, and how the service is billed. The good news: many people already have the raw genetic data needed for a pharmacogenetic report without realizing it, which is by far the cheapest path.
Pharmacogenetic results inform prescribing decisions but do not replace them. Never stop or change a medication based on a pharmacogenetic report alone — always discuss findings with your prescribing clinician.
Provider-ordered clinical pharmacogenetic panels — GeneSight, Genomind, OneOme RightMed, Mayo Clinic, Invitae's PGx panel — generally land in the $250 to $2,000 range. Insurance coverage varies widely; some plans cover psychiatric PGx testing with a clinical indication, and some do not. These tests include lab work, a new DNA sample, and a clinician-directed report.
Several direct-to-consumer PGx companies sell kits without requiring a prescription, typically in the $150 to $500 range. The gap between DTC and clinical pricing largely reflects the difference in panel size, interpretation depth, and whether a clinician is involved.
If you already have 23andMe, AncestryDNA, MyHeritage, or whole genome sequencing data, the lab work is already paid for. Services like Gene2Rx generate a comprehensive pharmacogenetic report from that existing raw data for under $50 in many cases, because nothing new has to be sequenced.
Insurance may cover pharmacogenetic testing when a clinician documents medical necessity — often for depression after prior treatment failures, cardiology drugs like clopidogrel, or chemotherapy with DPYD/TPMT concerns. Coverage rules vary by payer, plan, and state. Even when covered, there can be substantial out-of-pocket costs. Paying directly for a report from your own raw data is often cheaper and faster than navigating insurance.
Regardless of which test you pay for, the clinically useful pharmacogenes are largely the same set.
Metabolizes about a quarter of prescribed drugs. A cheap pharmacogenetic analysis that covers CYP2D6 well is far more useful than an expensive one that doesn't handle the gene's complexity. When comparing prices, it is worth checking how each service handles CYP2D6 star alleles.
Required for accurate SSRI selection and dosing, clopidogrel interpretation, and PPI titration. Any pharmacogenetic report — cheap or expensive — should include it.
The pair that guides warfarin dosing. Particularly relevant for older adults and anyone at risk of needing anticoagulation.
Statin muscle pain risk. Inexpensive to analyze but high real-world value for anyone on a statin.
Two reports at very different price points can contain largely the same metabolizer phenotype assignments if they cover the same genes and use the same guideline source (CPIC, FDA). When comparing cost, it is more useful to look at gene coverage and guideline citations than at price alone.
Pharmacogenetic testing is most cost-effective when you already have genetic data (23andMe, AncestryDNA, MyHeritage, or WGS) or when you are making a medication decision where the cost of a poor outcome is significant — for example starting an antidepressant, clopidogrel, a chemotherapy with DPYD or TPMT considerations, or chronic statin therapy. For anyone on long-term medications, the report has lifelong utility because your DNA does not change.
Learn how genetics may affect your response to these related medications:
The cheapest option is usually to reuse genetic data you already have — 23andMe, AncestryDNA, MyHeritage, or a WGS VCF — and pay only for the interpretation. That can bring the cost under $50, compared with $250 to $2,000 for a clinical panel that includes new lab work.
GeneSight is covered by some Medicare plans and some commercial insurers when ordered by a clinician for specific psychiatric indications after prior treatment failures. Coverage depends on the plan and the clinical documentation. Many people still pay out of pocket.
23andMe's Health + Ancestry service includes a limited pharmacogenetic section covering a handful of drugs and genes. It is narrower than a dedicated pharmacogenetic service like Gene2Rx, which extracts additional PGx variants from the same raw data and covers 100+ medications.
Not always — but not always worse either. What matters is gene coverage, adherence to published guidelines (CPIC, FDA), and how well complex genes like CYP2D6 are handled. A $30 report built on your existing raw data can cover the same actionable genes as a $500 panel; the main differences are typically in panel breadth and whether a clinician is involved in interpretation.
No. Many direct-to-consumer pharmacogenetic services, including analyses of existing 23andMe or AncestryDNA data, can be ordered by anyone. You should share the results with a clinician before acting on them, but you do not need a prescription to obtain them.
Find out how your DNA may influence your response to Sertraline and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator